Clinical trials: Psoriasis Vulgaris
Psoriasis Vulgaris
A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas
An international, multi-centre, prospective, randomised, double-blind, active-controlled, 2-arm, parallel group, 8-week, phase 3 clinical study in paediatric patients (aged 6 to 17 years) with psoriasis vulgaris on the face and…
- Trial name
- NCT01007591
- Testing
- LEO 80190, Hydrocortisone
- Where
- France
- Volunteers
- 40 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris
An international, multi-centre, prospective, randomised, double-blind, 4-arm, placebo controlled, parallel group study with 12 weeks once daily oral treatment in subjects with psoriasis vulgaris.
- Trial name
- NCT01116895
- Testing
- LEO 22811
- Where
- 2 sites in Canada, France
- Volunteers
- 63 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
The purpose of the study is to evaluate the anti-psoriatic effect of LEO 90100 cutaneous spray ointment, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.
- Trial name
- NCT01347255
- Testing
- LEO90100 cutaneous spray, ointment, LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate, LEO 90100 cutaneous spray, ointment, vehicle
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris
The purpose of this study is to investigate whether LEO 90100 and calcipotriol plus betamethasone are effective in the treatment of psoriasis vulgaris.
- Trial name
- NCT01536886
- Testing
- LEO 90100, Betamethasone plus calcipotriol, Ointment vehicle
- Where
- 39 sites in United States
- Volunteers
- 376 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
LEO 90100 in the Treatment of Psoriasis Vulgaris
The purpose of this study is to investigate whether LEO 90100, calcipotriol and betamethasone are effective in the treatment of psoriasis vulgaris.
- Trial name
- NCT01536938
- Testing
- LEO 90100, Calcipotriol, Betamethasone
- Where
- 33 sites in United States
- Volunteers
- 303 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris
A Phase 2 Maximal Use Systemic Exposure (MUSE) study evaluating the safety and efficacy of LEO 90100 used once daily in subjects with extensive psoriasis vulgaris.
- Trial name
- NCT01600222
- Testing
- LEO 90100
- Where
- 10 sites in Canada
- Volunteers
- 37 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris
Patients with psoriasis vulgaris of the trunk and/or limbs are randomised to treatment with: 1. 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8 weeks of calcipotriol cream 2.
- Trial name
- NCT00216892
- Testing
- Calcipotriol, (calcipotriol + betamethasone)
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 1,032 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris
This study will evaluate the efficacy and safety of calcipotriol plus betamethasone dipropionate ointment compared with calcipotriol ointment in the treatment of patients with psoriasis vulgaris for a duration of 4 weeks.
- Trial name
- NCT00248456
- Testing
- Calcipotriol plus betamethasone dipropionate ointment
- Where
- China
- Volunteers
- 320 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris
The objective of the study is to compare the use of calcipotriol plus betamethasone dipropionate gel with betamethasone dipropionate in the gel vehicle, calcipotriol in the gel vehicle and the gel vehicle alone when used in…
- Trial name
- NCT00263718
- Testing
- Calcipotriol plus betamethasone dipropionate (LEO 80185) gel
- Where
- 5 sites in Canada, Germany and 3 more
- Volunteers
- 360 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects
The purpose of this first-in-man trial is to determine the safety and tolerability of ascending single and multiple doses of LEO 22811 in healthy male subjects as well as to determine the safety and tolerability of single oral…
- Trial name
- NCT00833872
- Testing
- LEO 22811
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris
The purpose of this trial is to compare the anti-psoriatic effect of a topical combination product containing clobetasol propionate and calcipotriol in an ointment formulation to the single components in the same vehicle using a…
- Trial name
- NCT01043224
- Testing
- Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis
The purpose of this trial is to compare the anti-psoriatic effect of eight different formulations of vitamin D analogues using a psoriasis plaque test design
- Trial name
- NCT01105286
- Testing
- Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris
The purpose of this study is to evaluate the effect of once daily use of LEO 80185 gel on the hypothalamic-pituitary-adrenal (HPA) axis and calcium metabolism in subjects with extensive psoriasis vulgaris.
- Trial name
- NCT01229098
- Testing
- LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)
- Where
- 10 sites in Canada
- Volunteers
- 102 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris
The purpose of this study is to evaluate the anti-psoriatic effect of LEO 27989 ointment and calcipotriol plus LEO 27989 ointment, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.
- Trial name
- NCT01297166
- Testing
- LEO 27989 ointment, Calcipotriol plus LEO 27989 ointment, Calcipotriol ointment
- Where
- France
- Volunteers
- 25 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris
The purpose of the study is to compare the 3 ointment formulations containing LEO 29102 plus calcipotriol and Daivonex® ointment and Diprosone® ointment and to compare LEO 29102 plus calcipotriol to LEO 29102 alone and to…
- Trial name
- NCT01466478
- Testing
- Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment, Ointment B: LEO 29102 2.5 mg/g ointment, Ointment C: Calcipotriol 50 µg/g ointment
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris
The purpose of this study is to evaluate the antipsoriatic effect of 5 different combinations of calcipotriol plus betamethasone dipropionate in Daivobet® gel vehicle in compared to Daivobet® gel in order to explore/find other…
- Trial name
- NCT01837576
- Testing
- Calcipotriol plus BDP gel in different doses
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100
The purpose of this study is to determine the skin irritation potential and sensitisation potential of LEO 90100 and the vehicle after repeated applications on the skin of healthy subjects.
- Trial name
- NCT01935869
- Testing
- LEO 90100, Vehicle, Petrolatum ointment
- Where
- France
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
A Vasoconstriction Study With LEO 90100
The purpose of this study is to compare the pharmacodynamic activity of LEO 90100 with Dermovate® cream, Dovobet® ointment, betamethasone dipropionate in LEO90100 vehicle, Synalar® ointment and LEO 90100 vehicle using a human…
- Trial name
- NCT01946386
- Testing
- LEO 90100 Aerosol, foam, Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle, LEO 90100 Aerosol, foam, vehicle
- Where
- France
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population
A phase 4 trial comparing the safety and efficacy of treatment with Xamiol® gel (calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)) once daily (as required) with Daivonex® scalp solution (calcipotriol 50 mcg/g)…
- Trial name
- NCT02533973
- Testing
- Xamiol® gel, Daivonex® scalp solution
- Where
- China
- Volunteers
- 951 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A
The purpose of this study is to evaluate the anti-psoriatic effect of injected Botulinum toxin type A compared to that of injected vehicle.
- Trial name
- NCT02577185
- Testing
- Botulinum Toxin Type A, Sodium chloride 9 mg/ml
- Where
- 2 sites in Denmark
- Volunteers
- 10 people
- Sponsor
- LEO Pharma